On 21 October 2021, the REsolution consortium held its first consortium meeting online with 30 participants. The REsolution consortium is a public-private research partnership supported by the Innovative Medicines Initiative (IMI), the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), with nine partners from academia and the pharmaceutical industry. With a duration of two years, the project aims at understanding how genetic variants in humans affect the function of cellular solute carrier transporters (SLCs).

Scientists from different work packages described the progress on the collection and annotation of human genetic variants for SLCs and associated phenotypes, the strategy to experimentally characterize selected mutations of prioritized SLCs, as well as the interpretation of variant effects based on structural information and compared to predicted effects by Variant Effect Predictors. Finally, participants discussed at the REsolution platform in GatherTown.

We would like to thank all participants for joining the evend and their feedback, and specially the speakers for their excellent and informative presentations!

For more information on the project, please visit: http://re-solute.eu/resolution